Oppenheimer Upgrades Compass Pathways on Growing Confidence in COMP360

Oppenheimer upgrades Compass Pathways to Outperform with a $15 target, citing rising conviction that COMP360 psilocybin therapy could become the first FDA-approved psychedelic treatment for depression.